If earnings reports from Canadian licensed medical cannabis producers did not prove that the market prefers cannabis oil to dried cannabis, then the numbers out of Health Canada should.
The number of Canadian medical marijuana patients continues to grow rapidly and as of March 31st, there were 167,764 registered patients (almost 30% higher than the prior quarter).
Health Canada reported that 5,673 kilograms of cannabis oil were sold during the quarter that ended on March 31st. This number is 38% higher than the prior quarter and 870% higher than the same quarter last year.
Numbers Show a Remarkable Trend Toward Cannabis Oil
When you look at the amount of dried cannabis sold, this number increased by less than 10% when compared the prior quarter and less than 30% when compared to the same quarter last year.
Numbers don’t lie and this helps confirm that smoking dried marijuana is declining. Licensed producers have recognized this trend and are focused on increasing capacity to satisfy the higher demand.
When compared to the prior quarter, the amount of dried cannabis in the licensed producers’ inventories increased by less than 0.3% while the amount of cannabis oil increased by almost 40%. When compared to the prior year, the amount of dried cannabis increased by less than 70% while the amount of cannabis oil increased by more than 265%.
A More Attractive Opportunity
Cannabis oil is in high demand and licensed producers have many reasons to want to capitalize on this opportunity. One of the main reasons why we are favorable on this trend is due to the fundamentals.
Cannabis oil costs the consumer more and is a higher-margin product. The combination of high demand and better fundamentals is a great situation for any licensed producer and we expect to see producers continue to focus on this side of the business.
Cannabis oil is also a great solution when a licensed producer has too much dried cannabis product. The process of turning dried product into oil increases the shelf life of medical cannabis.
We are excited about this trend and believe the following firms are best levered to this growth opportunity: Canopy Growth (WEED.TO) (TWMJF), Aphria (APH.TO) (APHQF), CanniMed Therapeutics Inc. (CMED.TO) (CMMDF), Aurora Cannabis (ACB.V) (ACBFF), MedReleaf (LEAF.TO).
Important Investor Disclosures
This report was authored by and is property of Technical420. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by Technical420 regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only